Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple device help curb malaria in children?

NCT ID NCT07712263

Prevention Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests whether a device called the Guardian spatial emanator, which releases mosquito-repelling ingredients into the air, can be effectively added to an existing program that distributes antibiotics to children in Niger. The goal is to see if this integrated approach can reduce malaria-related clinic visits in children under 5. Researchers will measure how many households receive and correctly use the devices, and whether the community accepts them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Guardian spatial emanator (a device that releases volatile ingredients to repel mosquitoes)
What this could lead to
If successful, this approach could provide a scalable, low-cost way to prevent malaria in high-transmission areas without relying solely on bed nets or drugs.
What could go wrong
This is an implementation study, not a controlled efficacy trial, so it may not prove the device directly reduces malaria cases. Real-world factors like incorrect placement or low acceptance could limit impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Centre de Santé Intégré (CSI) catchment area participating in the AVENIR II azithromycin mass drug administration program * Located in a high malaria transmission setting in the study area * Randomly selected from the eligible pool for participation * Household located within a selected CSI catchment area * Verbal consent provided by the head of household for household-level study activities * Verbal consent provided by the CSI chief for CSI-level participation Exclusion Criteria: * CSI catchment area not participating in the AVENIR II azithromycin mass drug administration program * Household not located within a selected CSI catchment area * Refusal of verbal consent by the head of household * Refusal of verbal consent by the CSI chief for CSI-level participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malaria are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malaria

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Program National de Santé Oculaire

    Niamey, Niger

More trials for these conditions

Other studies related to the condition(s) this trial covers.